 |
 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
16 February 1999 | Volume 130 Issue 4 Part 1 | Pages 262-268
Background: In longitudinal studies, greater mammographic density is associated with an increased risk for breast cancer.
Objective: To assess differences between placebo, estrogen, and three estrogen–progestin regimens on change in mammographic density.
Design: Subset analysis of a 3-year, multicenter, double-blind, randomized, placebo-controlled trial.
Setting: Seven ambulatory study centers.
Participants: 307 of the 875 women in the Postmenopausal Estrogen/Progestin Interventions Trial. Participants had a baseline mammogram and at least one follow-up mammogram available, adhered to treatment, had not taken estrogen for at least 5 years before baseline, and did not have breast implants.
Intervention: Treatments were placebo, conjugated equine estrogens (CEE), CEE plus cyclic medroxyprogesterone acetate (MPA), CEE plus daily MPA, and CEE plus cyclic micronized progesterone (MP).
Measurements: Change in radiographic density (according to American College of Radiology Breast Imaging Reporting and Data System grades) on mammography.
Results: Almost all increases in mammographic density occurred within the first year. At 12 months, the percentage of women with density grade increases was 0% (95% CI, 0.0% to 4.6%) in the placebo group, 3.5% (CI, 1.0% to 12.0%) in the CEE group, 23.5% (CI, 11.9% to 35.1%) in the CEE plus cyclic MPA group, 19.4% (CI, 9.9% to 28.9%) in the CEE plus daily MPA group, and 16.4% (CI, 6.6% to 26.2%) in the CEE plus cyclic MP group. At 12 months, the odds of an increase in mammographic density were 13.1 (95% CI, 2.4 to 73.3) with CEE plus cyclic MPA, 9.0 (CI, 1.6 to 50.1) with CEE plus daily MPA, and 7.2 (CI, 1.3 to 40.0) with CEE plus cyclic micronized progesterone compared with CEE alone.
Conclusions: Further study of the magnitude and meaning of increased mammographic density due to use of estrogen and estrogen–progestins is warranted because mammographic density may be a marker for risk for breast cancer.
*For a partial list of the PEPI Investigators, see Appendix.
Author and Article Information
From University of California, Los Angeles, School of Medicine, Los Angeles, California; Wake Forest School of Medicine, Winston-Salem, North Carolina; Johns Hopkins University and University of Maryland Medical School, Baltimore, Maryland; and University of California at San Diego, San Diego, California.
Grant Support: The PEPI Trial is supported by cooperative agreement research grants U01-HL40154, U01-HL40185, UL-HL40195, U01-HL40205, U01-HL40207, U01-HL40231, U01-HL40232, and U01-HL40273 from the National Heart, Lung, and Blood Institute; the National Institute of Child Health and Human Development; the National Institute of Arthritis and Musculoskeletal and Skin Diseases; the National Institute of Diabetes and Digestive and Kidney Diseases; and the National Institute on Aging. Packaged medication and placebos were provided by Wyeth-Ayerst Laboratories, the Schering-Plough Research Institute, and the Upjohn Company. For this work, Dr. Greendale was supported by the Iris Cantor-UCLA Women's Center and the UCLA Center of Excellence in Women's Health (PHS 282-97-0025).
Requests for Reprints: Gail A. Greendale, MD, Division of Geriatrics, University of California, Los Angeles, School of Medicine, 10945 Le Conte Avenue, Suite 2339, Los Angeles, CA 90095-1687.
Current Author Addresses: Dr. Greendale: Division of Geriatrics, University of California, Los Angeles, School of Medicine, 10945 Le Conte Avenue, Suite 2339, Los Angeles, CA 90095-1687.
Dr. Reboussin and Ms. Wasilauskas: Department of Public Health Sciences, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1063.
Dr. Sie: Radia Medical Imaging, 1632 116th Avenue, NE, Suite D, Bellevue, WA 98004-3035.
Dr. Singh: Advanced Radiology, 7253 Ambassador Road, Baltimore, MD 21244-2714.
Dr. Olson: Radiology Department, University of California, San Diego, Medical Center-Hillcrest, 200 West Arbor Drive, San Diego, CA 92103-8756.
Dr. Gatewood: Radiology and Radiological Science, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287-5999.
Dr. Bassett: Radiological Sciences, University of California, Los Angeles, BL-428 CHS, Box 951721, Los Angeles, CA 90095-1721.
Dr. Bush: Department of Epidemiology and Preventive Medicine, University of Maryland Medical School, Howard Hall, Room 133, 660 West Redwood Street, Baltimore, MD 21201-1596.
Dr. Barrett-Connor: Department of Family and Preventive Medicine, University of California, San Diego, Clinical Science Building, Room 347, 0628, 9500 Gilman Drive, La Jolla, CA 92093-0628. ARTICLE
Effects of Estrogen and Estrogen–Progestin on Mammographic Parenchymal Density
This article has been cited by other articles:
|
|
 |
|
  M. Verheus, C. H. van Gils, S. Kreijkamp-Kaspers, L. Kok, P. H.M. Peeters, D. E. Grobbee, and Y. T. van der Schouw Soy Protein Containing Isoflavones and Mammographic Density in a Randomized Controlled Trial in Postmenopausal Women Cancer Epidemiol. Biomarkers Prev., October 1, 2008; 17(10): 2632 - 2638. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. E. Rohan, A. Negassa, R. T. Chlebowski, N. L. Lasser, A. McTiernan, R. S. Schenken, M. Ginsberg, S. Wassertheil-Smoller, and D. L. Page Estrogen plus Progestin and Risk of Benign Proliferative Breast Disease Cancer Epidemiol. Biomarkers Prev., September 1, 2008; 17(9): 2337 - 2343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Crandall, M. Guan, G. A. Laughlin, G. A. Ursin, F. Z. Stanczyk, S. A. Ingles, E. Barrett-Connor, and G. A. Greendale Increases in Serum Estrone Sulfate Level Are Associated with Increased Mammographic Density during Menopausal Hormone Therapy Cancer Epidemiol. Biomarkers Prev., July 1, 2008; 17(7): 1674 - 1681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Terry, D. S.M. Buist, A. Trentham-Dietz, T. M. James-Todd, and Y. Liao Nonsteroidal Anti-inflammatory Drugs and Change in Mammographic Density: A Cohort Study Using Pharmacy Records on Over 29,000 Postmenopausal Women Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1088 - 1095. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kerlikowske, D. S. M. Buist, R. Walker, and D. L. Miglioretti Response: Re: Declines in Invasive Breast Cancer and Use of Postmenopausal Hormone Therapy in a Screening Mammography Population J Natl Cancer Inst, April 16, 2008; 100(8): 599 - 599. [Full Text] [PDF]
|
|
|
|
|
|
K. Kerlikowske, D. L. Miglioretti, D. S. M. Buist, R. Walker, and P. A. Carney Declines in Invasive Breast Cancer and Use of Postmenopausal Hormone Therapy in a Screening Mammography Population J Natl Cancer Inst, September 5, 2007; 99(17): 1335 - 1339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Biglia, L. Mariani, L. Sgro, P. Mininanni, G. Moggio, and P. Sismondi Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment Endocr. Relat. Cancer, September 1, 2007; 14(3): 549 - 567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. J.B. van Duijnhoven, P. H.M. Peeters, R. M.L. Warren, S. A. Bingham, P. A.H. van Noord, E. M. Monninkhof, D. E. Grobbee, and C. H. van Gils Postmenopausal Hormone Therapy and Changes in Mammographic Density J. Clin. Oncol., April 10, 2007; 25(11): 1323 - 1328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kerlikowske, L. Ichikawa, D. L. Miglioretti, D. S. M. Buist, P. M. Vacek, R. Smith-Bindman, B. Yankaskas, P. A. Carney, and R. Ballard-Barbash Longitudinal Measurement of Clinical Mammographic Breast Density to Improve Estimation of Breast Cancer Risk J Natl Cancer Inst, March 7, 2007; 99(5): 386 - 395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Zhang, J. E. Manson, K. M. Rexrode, N. R. Cook, J. E. Buring, and I-M. Lee Use of Oral Conjugated Estrogen Alone and Risk of Breast Cancer Am. J. Epidemiol., March 1, 2007; 165(5): 524 - 529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Lyytinen, E. Pukkala, and O. Ylikorkala Breast Cancer Risk in Postmenopausal Women Using Estrogen-Only Therapy Obstet. Gynecol., December 1, 2006; 108(6): 1354 - 1360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Fabian and B. F. Kimler Mammographic Density: Use in Risk Assessment and as a Biomarker in Prevention Trials J. Nutr., October 1, 2006; 136(10): 2705S - 2708S. [Full Text] [PDF]
|
|
|
|
 |
|
 C T. Erel, L. M Senturk, and S. Kaleli Tibolone and breast cancer. Postgrad. Med. J., October 1, 2006; 82(972): 658 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Crandall, A. Karlamangla, M.-H. Huang, G. Ursin, M. Guan, and G. A. Greendale Association of New-Onset Breast Discomfort With an Increase in Mammographic Density During Hormone Therapy Arch Intern Med, August 14, 2006; 166(15): 1578 - 1584. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C J Whitaker, C M Kelly, K Faulkner, and E C Stamp Influence of menopausal status and use of hormone replacement therapy on radiation dose from mammography in routine breast screening. Br. J. Radiol., July 1, 2006; 79(943): 597 - 602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. F. Boyd, L. J. Martin, Q. Li, L. Sun, A. M. Chiarelli, G. Hislop, M. J. Yaffe, and S. Minkin Mammographic density as a surrogate marker for the effects of hormone therapy on risk of breast cancer. Cancer Epidemiol. Biomarkers Prev., May 1, 2006; 15(5): 961 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Stefanick, G. L. Anderson, K. L. Margolis, S. L. Hendrix, R. J. Rodabough, E. D. Paskett, D. S. Lane, F. A. Hubbell, A. R. Assaf, G. E. Sarto, et al. Effects of Conjugated Equine Estrogens on Breast Cancer and Mammography Screening in Postmenopausal Women With Hysterectomy JAMA, April 12, 2006; 295(14): 1647 - 1657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J.B. van Duijnhoven, P. H.M. Peeters, R. M.L. Warren, S. A. Bingham, A. G. Uitterlinden, P. A.H. van Noord, E. M. Monninkhof, D. E. Grobbee, and C. H. van Gils Influence of Estrogen Receptor {alpha} and Progesterone Receptor Polymorphisms on the Effects of Hormone Therapy on Mammographic Density. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 462 - 467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Greendale, S. L. Palla, G. Ursin, G. A. Laughlin, C. Crandall, M. C. Pike, and B. A. Reboussin The Association of Endogenous Sex Steroids and Sex Steroid Binding Proteins with Mammographic Density: Results from the Postmenopausal Estrogen/Progestin Interventions Mammographic Density Study Am. J. Epidemiol., November 1, 2005; 162(9): 826 - 834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Berube, C. Diorio, B. Masse, N. Hebert-Croteau, C. Byrne, G. Cote, M. Pollak, M. Yaffe, and J. Brisson Vitamin D and Calcium Intakes from Food or Supplements and Mammographic Breast Density Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1653 - 1659. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Aiello, S. S. Tworoger, Y. Yasui, F. Z. Stanczyk, J. Potter, C. M. Ulrich, M. Irwin, and A. McTiernan Associations among Circulating Sex Hormones, Insulin-Like Growth Factor, Lipids, and Mammographic Density in Postmenopausal Women Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1411 - 1417. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F.-P. Chen, Y.-C. Cheung, L.-F. Teng, and Y.-K. Soong The relationship between mammographic density and duration of hormone therapy: effects of estrogen and estrogen-progestin Hum. Reprod., June 1, 2005; 20(6): 1741 - 1745. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Kavanagh, J. Cawson, G. B. Byrnes, G. G. Giles, G. Marr, B. Tong, D. M. Gertig, and J. L. Hopper Hormone Replacement Therapy, Percent Mammographic Density, and Sensitivity of Mammography Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1060 - 1064. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. M. Barnabei, B. B. Cochrane, A. K. Aragaki, I. Nygaard, R. S. Williams, P. G. McGovern, R. L. Young, E. C. Wells, M. J. O'Sullivan, B. Chen, et al. Menopausal Symptoms and Treatment-Related Effects of Estrogen and Progestin in the Women's Health Initiative Obstet. Gynecol., May 1, 2005; 105(5): 1063 - 1073. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kerlikowske, J. Shepherd, J. Creasman, J. A. Tice, E. Ziv, and S. R. Cummings Are Breast Density and Bone Mineral Density Independent Risk Factors for Breast Cancer? J Natl Cancer Inst, March 2, 2005; 97(5): 368 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Li, L. Sun, N. Miller, T. Nicklee, J. Woo, L. Hulse-Smith, M.-S. Tsao, R. Khokha, L. Martin, and N. Boyd The Association of Measured Breast Tissue Characteristics with Mammographic Density and Other Risk Factors for Breast Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2005; 14(2): 343 - 349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Pearce, J. N. Hirschhorn, A. H. Wu, N. P. Burtt, D. O. Stram, S. Young, L. N. Kolonel, B. E. Henderson, D. Altshuler, and M. C. Pike Clarifying the PROGINS Allele Association in Ovarian and Breast Cancer Risk: A Haplotype-Based Analysis J Natl Cancer Inst, January 5, 2005; 97(1): 51 - 59. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Missmer, A. H. Eliassen, R. L. Barbieri, and S. E. Hankinson Endogenous Estrogen, Androgen, and Progesterone Concentrations and Breast Cancer Risk Among Postmenopausal Women J Natl Cancer Inst, December 15, 2004; 96(24): 1856 - 1865. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ziv, J. Tice, R. Smith-Bindman, J. Shepherd, S. Cummings, and K. Kerlikowske Mammographic Density and Estrogen Receptor Status of Breast Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2004; 13(12): 2090 - 2095. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Banks, G. Reeves, V. Beral, D. Bull, B. Crossley, M. Simmonds, E. Hilton, S. Bailey, N. Barrett, P. Briers, et al. Influence of personal characteristics of individual women on sensitivity and specificity of mammography in the Million Women Study: cohort study BMJ, August 28, 2004; 329(7464): 477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ursin, S. L. Palla, B. A. Reboussin, S. Slone, C. Wasilauskas, M. C. Pike, and G. A. Greendale Post-Treatment Change in Serum Estrone Predicts Mammographic Percent Density Changes in Women Who Received Combination Estrogen and Progestin in the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial J. Clin. Oncol., July 15, 2004; 22(14): 2842 - 2848. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Decensi, B. Bonanni, L. Baglietto, A. Guerrieri-Gonzaga, F. Ramazzotto, H. Johansson, C. Robertson, I. Marinucci, F. Mariette, M. T. Sandri, et al. A Two-by-Two Factorial Trial Comparing Oral with Transdermal Estrogen Therapy and Fenretinide with Placebo on Breast Cancer Biomarkers Clin. Cancer Res., July 1, 2004; 10(13): 4389 - 4397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Pazol, M. E. Wilson, and K. Wallen Medroxyprogesterone Acetate Antagonizes the Effects of Estrogen Treatment on Social and Sexual Behavior in Female Macaques J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2998 - 3006. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The Women's Health Initiative Steering Committee Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial JAMA, April 14, 2004; 291(14): 1701 - 1712. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. O. Lillie, L. Bernstein, S. A. Ingles, W. J. Gauderman, G. E. Rivas, V. Gagalang, T. Krontiris, and G. Ursin Polymorphism in the Androgen Receptor and Mammographic Density in Women Taking and Not Taking Estrogen and Progestin Therapy Cancer Res., February 15, 2004; 64(4): 1237 - 1241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Harvey and V. E. Bovbjerg Quantitative Assessment of Mammographic Breast Density: Relationship with Breast Cancer Risk Radiology, January 1, 2004; 230(1): 29 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kerlikowske, D. L. Miglioretti, R. Ballard-Barbash, D. L. Weaver, D. S.M. Buist, W. E. Barlow, G. Cutter, B. M. Geller, B. Yankaskas, S. H. Taplin, et al. Prognostic Characteristics of Breast Cancer Among Postmenopausal Hormone Users in a Screened Population J. Clin. Oncol., December 1, 2003; 21(23): 4314 - 4321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Gapstur, P. Lopez, L. A. Colangelo, J. Wolfman, L. Van Horn, and R. E. Hendrick Associations of Breast Cancer Risk Factors with Breast Density in Hispanic Women Cancer Epidemiol. Biomarkers Prev., October 1, 2003; 12(10): 1074 - 1080. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-C. Hong, H. J. Thompson, C. Jiang, G. L. Hammond, D. Tritchler, M. Yaffe, and N. F. Boyd Val158Met Polymorphism in Catechol-O-methyltransferase Gene Associated with Risk Factors for Breast Cancer Cancer Epidemiol. Biomarkers Prev., September 1, 2003; 12(9): 838 - 847. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Chlebowski, S. L. Hendrix, R. D. Langer, M. L. Stefanick, M. Gass, D. Lane, R. J. Rodabough, M. A. Gilligan, M. G. Cyr, C. A. Thomson, et al. Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women: The Women's Health Initiative Randomized Trial JAMA, June 25, 2003; 289(24): 3243 - 3253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. H. Gann and M. Morrow Combined Hormone Therapy and Breast Cancer: A Single-Edged Sword JAMA, June 25, 2003; 289(24): 3304 - 3306. [Full Text] [PDF]
|
|
|
|
|
|
E. Ziv, J. Shepherd, R. Smith-Bindman, and K. Kerlikowske Mammographic Breast Density and Family History of Breast Cancer J Natl Cancer Inst, April 2, 2003; 95(7): 556 - 558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Chlebowski and A. McTiernan Biological Significance of Interventions That Change Breast Density J Natl Cancer Inst, January 1, 2003; 95(1): 4 - 5. [Full Text] [PDF]
|
|
|
|
|
|
G. A. Greendale, B. A. Reboussin, S. Slone, C. Wasilauskas, M. C. Pike, and G. Ursin Postmenopausal Hormone Therapy and Change in Mammographic Density J Natl Cancer Inst, January 1, 2003; 95(1): 30 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. K. Weiss, R. T. Burkman, K. L. Cushing-Haugen, L. F. Voigt, M. S. Simon, J. R. Daling, S. A. Norman, L. Bernstein, G. Ursin, P. A. Marchbanks, et al. Hormone Replacement Therapy Regimens and Breast Cancer Risk Obstet. Gynecol., December 1, 2002; 100(6): 1148 - 1158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. M. Barnabei, D. Grady, D. W. Stovall, J. A. Cauley, F. Lin, C. A. Stuenkel, M. L. Stefanick, and J. H. Pickar Menopausal Symptoms in Older Women and the Effects of Treatment With Hormone Therapy Obstet. Gynecol., December 1, 2002; 100(6): 1209 - 1218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Humphrey, M. Helfand, B. K.S. Chan, and S. H. Woolf Breast Cancer Screening: A Summary of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, September 3, 2002; 137(5_Part_1): 347 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Writing Group for the Women's Health Initiative In Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial JAMA, July 17, 2002; 288(3): 321 - 333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Ganz, S. A. Castellon, and D. H. S. Silverman Estrogen, Tamoxifen, and the Brain J Natl Cancer Inst, April 17, 2002; 94(8): 547 - 549. [Full Text] [PDF]
|
|
|
|
|
|
B. Ettinger, A. Pressman, and A. Van Gessel Low-Dosage Esterified Estrogens Opposed by Progestin at 6-Month Intervals Obstet. Gynecol., August 1, 2001; 98(2): 205 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Rutter, M. T. Mandelson, M. B. Laya, and S. Taplin Changes in Breast Density Associated With Initiation, Discontinuation, and Continuing Use of Hormone Replacement Therapy JAMA, January 10, 2001; 285(2): 171 - 176. [Abstract] [Full Text] [PDF]
|
|
Article
